O
SPRB

OrbiMed’s Spruce Biosciences SPRB Stock Holding History

OrbiMed’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
+200,000
New +$11.2M 0.2% 83

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

OrbiMed's SPRB Position: Q2 2026 in Review

OrbiMed opened a new position in Spruce Biosciences (SPRB) in Q2 2026: 200,000 shares worth $10.8M. The stake represents 0.2% of the portfolio and ranks #83 among its holdings.

63 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • OrbiMed held 200,000 shares of Spruce Biosciences worth $10.8M as of Q2 2026.
  • Spruce Biosciences was a new OrbiMed position in Q2 2026.
  • Spruce Biosciences made up 0.2% of OrbiMed's portfolio in Q2 2026, its #83 holding.
  • 63 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.